Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

5:17 PM ET Form 4
Insider Selling Customers Bancorp, Inc. CUBI

Customers Bancorp EVP, Head of Corp Devel & IR Philip Watkins Sells $474K of Stock

Philip Watkins, EVP, Head of Corp Devel & IR, sold 5,500 shares of Customers Bancorp, Inc. at $86.17 a share, worth $474K in total on Nov 2, 2026. Shares held after the trade: 41,102 (-11.8%).

Value
$474K
Shares
5,500
Price
$86.17
Role
EVP, Head of Corp Devel & IR
Holding change
-11.8%
Trade date
Nov 2, 2026
5:16 PM ET 10-Q
Financial Results Adma Biologics, Inc. ADMA

Adma Biologics Q3 2026 Results: Net Income $49.9M, Up 36.9% YoY

ADMA Biologics reported 221,854,389 shares of common stock outstanding as of October 30, 2026, and is classified as a large accelerated filer. The company continues to focus on the commercialization of its primary products, ASCENIV and BIVIGAM, while managing a portfolio that includes Nabi-HB and a network of plasma collection centers.

Key figure
Net income $49.9M · +36.9% YoY
5:15 PM ET 8-K
Nasdaq/NYSE Compliance Notice Cayson Acquisition Corp CAPN

Cayson Acquisition Nasdaq/NYSE Compliance Notice

Cayson Acquisition Corp received a notice from Nasdaq on October 29, 2026, indicating that the company failed to regain compliance with the Minimum Total Holders Rule (Listing Rule 5450(a)(2)) during its extension period. Consequently, Nasdaq has initiated delisting procedures for the company's securities. The company has appealed the determination to maintain its listing while it works to provide documentation establishing the required 400 total holders.

Counterparty
Nasdaq
5:15 PM ET 8-K
Loan & Debt Kenvue Inc. KVUE

Kenvue $7B Debt Financing with Kimberly-Clark Corporation

Kimberly-Clark Corporation completed exchange offers for up to $7 billion of Kenvue LLC's outstanding senior notes in exchange for new Kimberly-Clark notes and cash. As part of the settlement, Kenvue retired and canceled approximately $6.38 billion in aggregate principal amount of its notes across seven different series and implemented amendments to eliminate substantially all restrictive covenants in the remaining outstanding notes.

Value
$7B
Counterparty
Kimberly-Clark Corporation
5:15 PM ET 10-Q
Financial Results Mineralys Therapeutics, Inc. MLYS

Mineralys Therapeutics Q3 2026 Results: Net Loss of $57.3M, Loss Widens

Mineralys Therapeutics reported a net loss of $337.7 million for the nine months ended September 30, 2026, driven by a $200 million upfront license amendment payment and increased R&D and G&A expenses. The company ended the period with $624.7 million in cash, cash equivalents, and investments, and is awaiting an FDA decision on its NDA for lorundrostat with a PDUFA date of December 22, 2026.

Key figure
Net loss $57.3M
5:15 PM ET 8-K
Financial Results National Healthcare Properties, Inc. NHP

National Healthcare Properties Financial Results

National Healthcare Properties reported Q3 2026 results highlighted by a 13.6% year-over-year increase in SHOP Same Store Cash NOI and the completion of $300 million in SHOP acquisitions. The company is executing a strategic shift toward a SHOP-only portfolio and utilized a new unsecured term loan to reduce secured debt.

Term
Q3 2026

“2026 continues to be a transformational year for the Company, and the third quarter included important milestones in our pursuit of a SHOP-only portfolio and an investment grade balance sheet. During the quarter, we succeeded in strategically increasing our same-store SHOP occupancy to improve our operating position into the fourth quarter, closed on more than $300 million of SHOP acquisitions at attractive yields, and utilized proceeds from our new unsecured term loan and the first tranche of our OMF exit to significantly reduce our secured debt.”

Michael Anderson, Chief Executive Officer and President
5:15 PM ET 10-Q
Financial Results Liberty Latin America Ltd. LILA

Liberty Latin America Q3 2026 Results: Net Loss of $70.9M

Liberty Latin America Ltd. filed its Q3 2026 report showing a complex debt structure with significant refinancing activities, including the repayment of the 2027 LPR Revolving Credit Facility. The company maintains a large accelerated filer status with 186.3 million total outstanding common shares across Class A, B, and C as of October 31, 2026.

Key figure
Net loss $70.9M
5:15 PM ET Form 4
Insider Selling Customers Bancorp, Inc. CUBI

Customers Bancorp Director T. Lawrence Way Sells $4.15M of Stock

T. Lawrence Way, Director, sold 49,519 shares of Customers Bancorp, Inc. at $83.88 to $85.16 a share (average $83.90) in 2 transactions, worth $4.15M in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 77,890 (-0.9%).

Value
$4.15M
Shares
49,519
Average price
$83.90
Role
Director
Holding change
-0.9%
Trade date
Oct 30, 2026 to Nov 2, 2026
5:15 PM ET 8-K
Financial Results Sandridge Energy Inc SD

Sandridge Energy Financial Results

SandRidge Energy reported Q3 2026 financial results with net income of $30.6 million and a 10% year-over-year increase in production to 20.9 MBoe per day. The company also declared a quarterly dividend of $0.13 per share and highlighted the closing of a bolt-on acquisition in the Cherokee Play.

Term
Q3 2026

“The Company continues to increase production versus last year, driven by our one-rig program in the Cherokee Play and the closing of the previously announced bolt-on acquisition, extending our efficient operations in the area. I continue to be amazed by the team's record of five years without a recordable safety incident while maintaining a low G&A burden and folding new assets into the portfolio. The Company has benefited from strong WTI prices this past quarter and year, with current WTI futures providing a potential tailwind through the end of the year and into next. This provides a positive backdrop for integrating the new assets into our development plans.”

Grayson Pranin, SandRidge’s President, Chief Executive Officer & Director
5:13 PM ET 8-K
Capital Raise WEC Energy Group, Inc. WEC

WEC Energy Group Capital Raise

WEC Energy Group entered into an equity distribution agreement to establish an at-the-market (ATM) offering program for up to $4.0 billion of its common stock. The program includes provisions for forward sale agreements with various financial institutions acting as sales agents and forward purchasers.

5:13 PM ET Form 4
Insider Buying Stride, Inc. LRN

Stride Director Brian A. Shepherd Buys $1.67M of Stock

Brian A. Shepherd, Director, bought 22,000 shares of Stride, Inc. at $74.40 to $76.90 a share (average $75.90) in 4 transactions, worth $1.67M in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 23,094 (+27.6%).

Value
$1.67M
Shares
22,000
Average price
$75.90
Role
Director
Holding change
+27.6%
Trade date
Nov 2, 2026 to Nov 3, 2026
5:13 PM ET 8-K
Loan & Debt Steris plc STE

Steris $1.6B Debt Financing with JPMorgan Chase Bank, N.A.

STERIS plc entered into a new $1.6 billion revolving credit agreement with JPMorgan Chase Bank and other lenders, replacing its existing 2024 facility. The new facility matures on November 4, 2031, and includes an accordion feature allowing for an incremental increase of up to $800 million. The proceeds will be used for general corporate purposes, including swingline borrowings and letters of credit.

Value
$1.6B
Counterparty
JPMorgan Chase Bank, N.A.
Term
5 years
5:13 PM ET Form 4
Insider Buying Lycia Therapeutics, Inc. LYCA

Lycia Therapeutics 10% Owner Venrock Healthcare Capital Partners III L.P. Buys $224K of Stock

Venrock Healthcare Capital Partners III L.P., 10% Owner, bought 8,305 shares of Lycia Therapeutics, Inc. at $26.95 a share, worth $224K in total on Nov 2, 2026. Shares held after the trade: 6,858,542 (+0.1%).

Value
$224K
Shares
8,305
Price
$26.95
Role
10% Owner
Holding change
+0.1%
Trade date
Nov 2, 2026
5:13 PM ET Form 4
Insider Selling CB Financial Services, Inc. CBFV

CB Financial Services SEVP and COO Jennifer L. George Sells $84K of Stock

Jennifer L. George, SEVP and COO, sold 2,080 shares of CB Financial Services, Inc. at $40.39 to $40.41 a share (average $40.39) in 2 transactions, worth $84K in total on Nov 2, 2026. Shares held after the trade: 13,170 (-2.1%).

Value
$84K
Shares
2,080
Average price
$40.39
Role
SEVP and COO
Holding change
-2.1%
Trade date
Nov 2, 2026
5:13 PM ET 8-K
Shareholder Meeting GRI Bio, Inc. GRI

GRI Bio Shareholder Meeting

GRI Bio held its 2026 Annual Meeting of Stockholders where shareholders elected W. Marc Hertz and David Szekeres as Class III directors and ratified WithumSmith+Brown, PC as the independent auditor. Stockholders also approved an amendment to the 2018 Equity Incentive Plan, increasing the share reserve by 546,529 shares and extending the evergreen provision to 2036.

5:13 PM ET 8-K
Financial Results AGL Private Credit Income Fund

AGL Private Credit Income Fund Financial Results

AGL Private Credit Income Fund reported its Q3 2026 financial results, generating $14.6 million in net investment income ($0.60 per share). The fund's net asset value (NAV) per share increased to $23.46 from $23.28 in the prior quarter, while the total portfolio fair value grew to $1.5 billion across 47 companies.

5:13 PM ET 10-Q
Financial Results Figma, Inc. FIG ▶ Call

Figma Q3 2026 Results: Net Loss of $81.3M, Loss Narrows

Figma, Inc. filed its Form 10-Q for the period ending October 30, 2026, reporting a multi-class share structure with 457.7 million Class A and 77.9 million Class B shares outstanding. The filing highlights significant risk factors related to rapid growth, AI competition, and the potential for third-party AI agents to circumvent existing pricing models.

Key figure
Net loss $81.3M
5:13 PM ET Form 4
Insider Selling Recursion Pharmaceuticals, Inc. RXRX

Recursion Pharmaceuticals Insider Blake Borgeson Sells $155K of Stock

Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals, Inc. at $3.88 a share, worth $155K in total on Nov 3, 2026. Shares held after the trade: 6,068,287 (-0.7%).

Value
$155K
Shares
40,000
Price
$3.88
Holding change
-0.7%
Trade date
Nov 3, 2026
5:13 PM ET 10-Q
Financial Results Vir Biotechnology, Inc. VIR

Vir Biotechnology Q3 2026 Results: Net Loss of $96.3M, Loss Narrows

Vir Biotechnology reported a significant increase in total revenues to $238.7 million for the nine months ended September 30, 2026, primarily driven by license and collaboration revenue. Despite this, the company recorded a net loss of $141.9 million for the same period, though this was a substantial improvement from the $395.1 million net loss in the prior year due to higher revenues and reduced research and development expenses.

Key figure
Net loss $96.3M
5:12 PM ET 8-K
Financial Results Fatpipe Inc FATN

Fatpipe Financial Results

FatPipe, Inc. reported its second quarter fiscal year 2027 financial results, achieving revenue of $4.83 million, a 22% increase year-over-year. The company swung to a net income of $1.2 million from a slight loss in the prior year period, driven by strong demand for its SD-WAN and cybersecurity solutions. Management highlighted a 24.1% Adjusted EBITDA margin and growth in recurring revenue as key performance drivers.

Term
Q2 2027

“We are pleased with our continued revenue growth and profitability this quarter, reflecting the strength of our business model and continued execution across the organization. We remain focused on expanding our channel partnerships, growing our customer base, and building on the momentum across our SD-WAN, cybersecurity, and network monitoring offerings.”

Dr. Ragula Bhaskar, CEO of FatPipe

“Our second quarter results reflect continued progress in growing our recurring revenue base. With revenue increasing 22% year-over-year and an Adjusted EBITDA margin of 24.1%, we continue to demonstrate our ability to deliver profitable growth while investing in strategic initiatives. We believe our financial position provides a strong foundation to expand our sales organization, strengthen our partner ecosystem, and pursue additional growth opportunities.”

Kanishka Ragula, CFO of FatPipe
5:12 PM ET 10-Q
Financial Results Natures Sunshine Products Inc NATR

Natures Sunshine Products Q3 2026 Results: Net Income $1.89M, Down 64.6% YoY

For the nine months ended September 30, 2026, Nature's Sunshine Products reported net sales of $356.5 million, remaining flat compared to the prior year, while net income attributable to common shareholders decreased to $10.5 million from $15.4 million. The company maintained a strong balance sheet with $89.4 million in cash and cash equivalents despite facing significant foreign exchange losses during the period.

Key figure
Net income $1.89M · -64.6% YoY
5:12 PM ET Form 4
Insider Selling Life360, Inc. LIF

Life360 Insider John Philip Coghlan Sells $183K of Stock

John Philip Coghlan sold 4,000 shares of Life360, Inc. at $45.29 to $46.69 a share (average $45.80) in 3 transactions, worth $183K in total on Nov 2, 2026. Shares held after the trade: 8,431 (-7.9%).

Value
$183K
Shares
4,000
Average price
$45.80
Holding change
-7.9%
Trade date
Nov 2, 2026
5:12 PM ET 10-Q
Financial Results Geron Corp GERN

Geron Q3 2026 Results: Turns Profitable, Net Income $1.35M

Geron Corporation reported a net income of $1.35 million for the third quarter of 2026, a significant improvement from the $18.4 million net loss in the same period of 2025, driven by a 27% increase in product revenue to $60.1 million. Despite the quarterly profit, the company recorded a net loss of $19.0 million for the first nine months of 2026 as it continues to manage high operating expenses and inventory investments.

Key figure
Net income $1.35M
5:12 PM ET 10-Q
Financial Results Seaport Entertainment Group Inc. SEG

Seaport Entertainment Group Q3 2026 Results: Net Loss of $8.38M, Loss Narrows

Seaport Entertainment Group Inc. reported total revenues of $79.7 million for the nine months ended September 30, 2026, a decrease from $100.9 million in the prior year period. The company's total assets decreased to $524.7 million from $650.1 million at year-end 2025, primarily due to the disposition of assets held for sale.

Key figure
Net loss $8.38M
5:12 PM ET 8-K
Financial Results Chord Energy Corp CHRD

Chord Energy Financial Results

Chord Energy reported Q3 2026 financial results with oil volumes of 165.5 MBopd, exceeding the top-end of guidance. The company raised its full-year 2026 oil volume guidance and increased its Adjusted Free Cash Flow expectations by approximately $200 million since August. Additionally, Chord announced the divestiture of non-operated Marcellus assets for $550 million, with closing expected in Q4 2026.

Term
Q3 2026

“Chord’s operational momentum continues and the team delivered solid results in the third quarter. Third quarter volumes were above the top-end of guidance and Chord raised FY26 oil volume guidance for the second time this year. We continue to execute on our strategy and make further progress on key projects, including our 4-mile program and base production enhancement. Chord also executed several third-party marketing agreements that, alongside other initiatives implemented over the past two years, increased annual run-rate savings to $225 million. Chord continues to drive efficiency through every aspect of the business, which pu”

Michael Lou, Chord Energy’s President and Chief Executive Officer
5:11 PM ET 8-K
Reverse Stock Split Invo Fertility, Inc. IVF

Invo Fertility Reverse Stock Split

INVO Fertility, Inc. implemented a 1-for-4 reverse stock split of its issued, outstanding, and authorized common stock effective October 30, 2026. The split reduced the number of outstanding shares to approximately 1.2 million and adjusted the authorized share count to 62.5 million to maintain compliance with Nasdaq listing requirements. Trading commenced on a split-adjusted basis under the existing symbol 'IVF' with a new CUSIP number.

5:11 PM ET 8-K
Licensing Deal Evommune, Inc. EVMN

Evommune Licensing Deal with Hinova Pharmaceuticals Inc. Worth $30M

Evommune has entered into an exclusive license agreement with Hinova Pharmaceuticals to develop and commercialize EVO570, a VAV1 molecular glue degrader, globally excluding Greater China. Evommune will pay $20 million upfront in cash and $10 million in pre-funded warrants, with Hinova eligible for up to $1.07 billion in additional milestone payments plus tiered royalties.

Value
$30M
Counterparty
Hinova Pharmaceuticals Inc.
Term
Royalty Term
5:11 PM ET 10-Q
Financial Results USA Compression Partners, LP USAC ▶ Call

USA Compression Partners Q3 2026 Results: Net Income $47.3M, Up 37.3% YoY

USA Compression Partners, LP reported its quarterly financial results for the period ended September 30, 2026, focusing on its natural gas compression services and contract operations. The filing includes detailed financial statements and management's discussion on operational efficiency and fleet utilization.

Key figure
Net income $47.3M · +37.3% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.